Examkin

Soru

Zorluk: ZorInfectious Diseases

An inpatient infectious disease consultation is requested for a 5454-year-old man who has been hospitalized for the past 33 weeks following an extensive bowel resection for acute mesenteric ischemia. Due to short bowel syndrome, he has been dependent on total parenteral nutrition administered via a right upper extremity peripherally inserted central catheter (PICC). Yesterday, the patient experienced a sudden onset of rigors and a temperature spike to 39.1∘C39.1^\circ\text{C} (102.4∘F102.4^\circ\text{F}). His blood pressure dropped to 105/65105/65 mm Hg with a pulse of 110110/min. Examination of the PICC insertion site revealed focal erythema and tenderness. The catheter was promptly removed, and empiric intravenous vancomycin and piperacillin-tazobactam were initiated. Today, the patient is afebrile and hemodynamically stable. Preliminary blood cultures from both the PICC tip and a peripheral draw are positive for *Staphylococcus aureus* in 44 out of 44 bottles. Final susceptibility results show the isolate is resistant to penicillin but susceptible to oxacillin, cefazolin, clindamycin, and vancomycin. Which of the following is the most appropriate next step in pharmacotherapy?

  1. Initiate intravenous cefazolin and stop current antibioticsCevap
  2. B
    Continue intravenous vancomycin and stop piperacillin-tazobactam
  3. C
    Continue intravenous piperacillin-tazobactam and stop vancomycin
  4. D
    Initiate intravenous ceftaroline and stop current antibiotics
  5. E
    Initiate oral linezolid and stop current antibiotics

Cevap

Initiate intravenous cefazolin and stop current antibiotics
The patient has a catheter-related bloodstream infection caused by methicillin-susceptible Staphylococcus aureus (MSSA), as indicated by the isolate's susceptibility to oxacillin. For MSSA bacteremia, targeted therapy with an intravenous beta-lactam agent, such as a first-generation cephalosporin (e.g., cefazolin) or an anti-staphylococcal penicillin (e.g., nafcillin, oxacillin), is the absolute standard of care. These agents provide superior bactericidal activity against MSSA compared to vancomycin, leading to faster microbiological clearance and significantly lower rates of mortality. Therefore, the empiric broad-spectrum regimen should be de-escalated to targeted intravenous cefazolin.

Adım Adım Çözüm

1
Analyze the blood culture and susceptibility results.
The pathogen is methicillin-susceptible Staphylococcus aureus (MSSA), confirmed by its susceptibility to oxacillin.
Identifying the specific organism and its resistance profile is essential for targeting antimicrobial therapy.
2
Evaluate the current empiric antibiotic regimen.
The patient is on vancomycin (covers MRSA) and piperacillin-tazobactam (covers Pseudomonas and Gram-negatives).
Empiric therapy is often broad to cover all likely pathogens, but must be de-escalated once culture data is available.
3
Determine the definitive standard of care for MSSA bacteremia.
Intravenous beta-lactams like cefazolin, nafcillin, or oxacillin are the superior agents of choice.
Beta-lactams clear MSSA bacteremia faster than vancomycin and are associated with significantly lower mortality rates.
4
Assess the appropriateness of oral step-down therapy.
Oral therapy is strictly contraindicated for this condition.
S. aureus bacteremia carries a high risk of endovascular seeding, requiring at least 14 days of continuous intravenous bactericidal therapy.

Anahtar Kavram

For methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, narrow-spectrum intravenous beta-lactams (e.g., cefazolin, nafcillin) are highly superior to vancomycin and should be initiated as soon as susceptibility is confirmed. Oral step-down therapy is contraindicated regardless of clinical improvement.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru